ClinicalTrials.gg
BiologicalDrug

Telitacicept clinical trials

Also written RC18.

studies test it
54
open now
27
in phase 3
18
first study started
2015

How each study uses telitacicept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the telitacicept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Telitacicept
33
Telitacicept 160mg
6
RC18-L
3
RC18 240 mg
3
RC18 160 mg
3

Development codes

RC18
13

Studies by the year they started

54 studies that test it; most in 2023 (13)

Studies that test telitacicept, by start year
YearStudies
20152
20171
20181
20193
20202
20213
20224
202313
202410
20257
20268

Who runs them

Industry 24 · Other 30

RemeGen Co., Ltd. (19) · Vor Biopharma (4) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3) · Chinese SLE Treatment And Research Group (3) · Renmin Hospital of Wuhan University (2) · Ruijin Hospital (2) · The Children's Hospital of Zhejiang University School of Medicine (2) · First Affiliated Hospital of Wenzhou Medical University (2)

Often tested with

Tested in the same studies.

Daratumumab (1) · IBI3034 (1) · Efgartigimod alfa (1) · Cyclophosphamide (1) · Belimumab (1) · Mycophenolic Acid (1) · Interleukin-2 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 12, 4 in phase 3

Studies that test telitacicept, phase 3 first.

Studies

Open first, then newest update. How each study uses telitacicept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 54

See all 54 studies that test telitacicept →

Given beside what is tested · 1 — telitacicept is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call telitacicept · ClinicalTrials.gg INT001851

  • MeSH (NLM) C000722462telitaciceptOne source ClinicalTrials.gov
  • UNII (FDA) 1FHM3D7Z49TELITACICEPTOne source FDA
  • NCI Thesaurus C166498TelitaciceptOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.